Shadma Fatima

Dr. Shadma Fatima is a molecular biologist specializing in precision medicine, immunology, and bioinformatics, with expertise in omics-driven cancer biomarker and drug discovery. Earning her Ph.D. from Monash University in 2017, she pioneered discoveries on BRAP2 and Imp13 in mammalian development. She leads the world’s first study on Secretory Phospholipase A2 in brain cancer, developing novel drugs and diagnostics that outperform standard treatments. Her innovations span glioblastoma, prostate cancer, and COVID-19 therapies. Recognized with multiple awards, Dr. Fatima is a published researcher, educator, and mentor, driving interdisciplinary collaborations to advance targeted therapies and non-invasive diagnostics in oncology and beyond. Her research has attracted over $1.7M across academic research and industry-based project grants. She has co-authored more than 25 publications in prestigious venues—e.g., Briefing in Bioinformatics (IF: 13.99), Cancers (IF  6.69), FASEB (IF: 5.834), Nature Sc Reports (IF: 4.996) Frontiers in nutrition (IF 7.8) demonstrating her research impact, leadership, and substantive contribution in advancement of research.